GleamWall
中文EN

FLGT Fulgent Genetics, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1674930 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.7%
TTM net income YoY-111.5%
TTM EPS YoY-135.1%
Revenue 3-yr CAGR4.9%
Net income 3-yr CAGR—

Margins

Gross margin33.8%
Operating margin-39.2%
Net margin-27.5%
FCF margin-0.4%
EBITDA margin-32.8%

Returns

ROE-8.6%
ROA-7.9%
ROIC (approx.)-10.7%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets8.7%
Debt / equity0.00x
Current ratio5.34x
Interest coverage-1,307.88x

Cash quality & payout

Operating cash flow / net income-0.16x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue4.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$90.41M$85.39M$71.14M$83.34M$84.07M$81.80M$73.46M$76.21M
Cost of revenue$58.47M$59.71M$49.65M$50.75M$48.56M$47.37M$45.12M$44.37M
Gross profit$31.95M$25.68M$21.49M$32.58M$35.51M$34.44M$28.35M$31.85M
R&D expense$13.64M$14.55M$14.18M$14.17M$13.86M$13.48M$12.39M$12.11M
SG&A expense$22.76M$27.20M$27.68M$41.65M$23.34M$26.39M$25.29M$24.34M
Operating income-$22.55M-$36.07M-$34.62M-$36.24M-$15.35M-$19.71M-$19.80M-$16.14M
Interest expense$7,000$59,000$17,000$16,000$28,000$17,000$14,000$40,000
Pretax income-$14.04M-$29.69M-$25.98M-$29.27M-$7.51M-$21.52M-$11.72M-$8.04M
Income tax-$704,000$29,000-$704,000-$5.62M-$683,000-$2.26M$176,000-$1.85M
Net income-$13.15M-$29.53M-$24.83M-$23.42M-$6.61M-$18.96M-$11.53M-$5.89M
EBITDA-$18.35M-$31.07M-$28.62M-$30.13M-$11.45M-$15.81M-$13.88M-$9.94M
EPS (diluted)————————
Weighted avg. shares (diluted)27.66M28.00M30.88M—30.75M30.54M30.83M—
Balance sheet
Cash & equivalents$86.79M$26.30M$23.40M$50.19M$117.64M$87.88M$67.28M$55.28M
Short-term investments$205.95M$230.73M$252.90M$285.88M———$202.96M
Receivables$62.49M$64.94M$69.28M$84.76M$71.19M$77.19M$71.48M$69.02M
Inventory$661,000$793,000$770,000—————
Current assets$383.74M$454.77M$479.04M$550.49M$507.37M$428.73M$416.78M$353.57M
PP&E, net$110.74M$113.07M$116.34M$112.55M$111.86M$110.22M$107.08M$105.55M
Goodwill$53.86M$53.86M$53.73M$25.08M$25.08M$22.05M$22.05M$22.05M
Intangibles$146.80M$149.26M$153.99M$133.28M$135.25M$135.25M$133.01M$134.98M
Total assets$1.08B$1.09B$1.16B$1.21B$1.21B$1.20B$1.21B$1.22B
Current liabilities$71.88M$71.76M$90.13M$84.97M$72.43M$71.33M$65.92M$72.90M
Total liabilities$94.22M$93.24M$112.22M$106.81M$93.81M$88.20M$82.97M$90.81M
Shareholders' equity$990.49M$1.00B$1.05B$1.11B$1.13B$1.12B$1.13B$1.13B
Shares outstanding27.76M27.52M28.85M31.08M30.85M30.61M30.62M30.84M
Cash flow statement
Operating cash flow$109.23M-$23.76M$7.10M-$78.14M$11.11M-$30.17M-$4.43M$25.02M
Capital expenditure$1.79M$3.86M$5.20M$4.98M$6.05M$6.83M$4.72M$3.78M
Free cash flow$107.44M-$27.62M$1.90M-$83.12M$5.06M-$37.00M-$9.15M$21.24M
Investing cash flow-$48.04M$50.80M$10.94M$11.15M$19.08M$53.40M$27.73M-$27.45M
Financing cash flow-$724,000-$24.23M-$44.83M-$534,000-$445,000-$2.64M-$11.17M-$327,000
Depreciation & amortization$4.20M$5.00M$6.00M$6.11M$3.90M$3.90M$5.92M$6.19M
Stock-based compensation$8.12M$8.62M$9.89M$9.28M$9.72M$10.04M$10.55M$10.41M
Share buybacks$251,000$23.80M$40.08M$0$0$2.21M$8.68M$0

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.